Hello friends..........................WISHING ALL STUDENTS, TEACHERS WORLDWIDE...A VERY HAPPY TEACHER'S DAY...............
I am happy to love being a teacher...and also blessed to guide many people along the way...................
PROUDLY, I RELEASE MY 15TH PPT, ON TEACHER'S DAY, REGARDING EPILEPSY AND SEIZURES...................
U will get all possible details that u need ....
Do review my ppt, and send me ur feedbacks.....
Thanks for reading and supporting my works till now...............
@rxvichu-alwz4uh!
Critical evaluation of biomedical literature - clinical pharmacyShaistaSumayya
Reviewing the ‘Biomedical Literature’ poses a great challenge to the clinical professionals.
Evaluating a scientific article is a complex task.
Knowledge of the standard anatomy of an article and idiosyncrasy of various types of studies will assist the reader to review the ‘Biomedical Literature’ efficiently
Biomedical Literature includes critical appraisal of the following contents:
Title
Abstract
Introduction
Objective
Materials and Methods
Study Designs
Bias
Statistics
Results and Analysis
Discussion and Conclusion
References
SCHIZOPHRENIA- A BRIEF INSIGHT....By Rxvichu!RxVichuZ
Hello friends....this is my 24th powerpoint..that I am uploading here in slideshare...
This ppt consists of SCHIZOPHRENIA...its causes...and management strategies............
This time, for a change, I have also included 2 explicit videos, that explain the vividness of the disease.................
Also ,home remedies for schizophrenia has been outlined, so that timely steps can be taken to prevent the disease progression n severity!!
Hoping that onlookers would go through this precise work..and mail or comment me their feedbacks!!
Thank you!!
Vishnu.R.Nair(rxvichu),
5th year Pharm.D,
National College of Pharmacy,
Kerala, India.
:) :)
Critical evaluation of biomedical literature - clinical pharmacyShaistaSumayya
Reviewing the ‘Biomedical Literature’ poses a great challenge to the clinical professionals.
Evaluating a scientific article is a complex task.
Knowledge of the standard anatomy of an article and idiosyncrasy of various types of studies will assist the reader to review the ‘Biomedical Literature’ efficiently
Biomedical Literature includes critical appraisal of the following contents:
Title
Abstract
Introduction
Objective
Materials and Methods
Study Designs
Bias
Statistics
Results and Analysis
Discussion and Conclusion
References
SCHIZOPHRENIA- A BRIEF INSIGHT....By Rxvichu!RxVichuZ
Hello friends....this is my 24th powerpoint..that I am uploading here in slideshare...
This ppt consists of SCHIZOPHRENIA...its causes...and management strategies............
This time, for a change, I have also included 2 explicit videos, that explain the vividness of the disease.................
Also ,home remedies for schizophrenia has been outlined, so that timely steps can be taken to prevent the disease progression n severity!!
Hoping that onlookers would go through this precise work..and mail or comment me their feedbacks!!
Thank you!!
Vishnu.R.Nair(rxvichu),
5th year Pharm.D,
National College of Pharmacy,
Kerala, India.
:) :)
Drug induced hematological disorders @rxvichu!!!RxVichuZ
This is my 35th powerpoint..published here in Google Slideshare...
And I wish to thank everyone who have supported me in my 2 year long journey......
This ppt is regarding DRUG INDUCED HEMATOLOGICAL DISORDERS, covering the definitions, causative drugs, pathophysiological mechanisms, manifestations,and management of 5 blood disorders.
Do go through this ppt, and send me ur reviews!!
Regards,
Vishnu.R.Nair.
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Applications of computers in Hospital Pharmacy- By RxVichuZ!RxVichuZ
This work deals with the precise applications of Computers in Hospital Pharmacy. Basically deals with Biostatistics & Research Methodology subject.
Hope it is worthwhile to the readers.
Happy reading!
- @ RxVichuZ!
Home remedies and patient counselling tips for ANEMIA-By rxvichu-alwz4uh!! :) :)RxVichuZ
Hello members....this is my 28th powerpoint..on exactly half of the date(14.09.2017)...lol
This presentation of mine, centralizes on ANEMIA, its introduction, causes, manifestations, and includes GENEROUS DETAILS, on 15 HOME REMEDIES, along with PATIENT COUNSELLING TIPS(DO'S and DONT'S).
This will surely be helpful for those who are studying about ANEMIA, those who indulge in patient counselling, and those who wish to read it for general reference purpose.
I am self-specializing in HOME REMEDY STUDY, and PATIENT COUNSELLING. So, for further details, you can also contact me.
Reviews, suggestions, and critical evaluations, are ALWAYS WELCOME!!
Regards,
Vishnu.R.Nair,
5th year Pharm.D,
National College of Pharmacy, Kerala, India.
Introduction to daily activities of clinical pharmacist.
Drug therapy monitoring,
Medication chart review
Clinical Progress
Pharmacist intervention
Detection and management of ADRs
A concise overview of pharmacoeconomics, health economics, various costs, various pharmacoeconomic study designs and its application in the field of medicine and drug development
Newer drugs approved by US-FDA - Rxvichu!!!RxVichuZ
This is my 22nd ppt............................
It contains HALF of the totl drugs approved by US-FDA for 2014
Consists of 20 drugs...out of 41
Do go through it.....and send ur reviews!
Regards,
Rxvichu-alwz4uh!
:)
Drug induced hematological disorders @rxvichu!!!RxVichuZ
This is my 35th powerpoint..published here in Google Slideshare...
And I wish to thank everyone who have supported me in my 2 year long journey......
This ppt is regarding DRUG INDUCED HEMATOLOGICAL DISORDERS, covering the definitions, causative drugs, pathophysiological mechanisms, manifestations,and management of 5 blood disorders.
Do go through this ppt, and send me ur reviews!!
Regards,
Vishnu.R.Nair.
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Applications of computers in Hospital Pharmacy- By RxVichuZ!RxVichuZ
This work deals with the precise applications of Computers in Hospital Pharmacy. Basically deals with Biostatistics & Research Methodology subject.
Hope it is worthwhile to the readers.
Happy reading!
- @ RxVichuZ!
Home remedies and patient counselling tips for ANEMIA-By rxvichu-alwz4uh!! :) :)RxVichuZ
Hello members....this is my 28th powerpoint..on exactly half of the date(14.09.2017)...lol
This presentation of mine, centralizes on ANEMIA, its introduction, causes, manifestations, and includes GENEROUS DETAILS, on 15 HOME REMEDIES, along with PATIENT COUNSELLING TIPS(DO'S and DONT'S).
This will surely be helpful for those who are studying about ANEMIA, those who indulge in patient counselling, and those who wish to read it for general reference purpose.
I am self-specializing in HOME REMEDY STUDY, and PATIENT COUNSELLING. So, for further details, you can also contact me.
Reviews, suggestions, and critical evaluations, are ALWAYS WELCOME!!
Regards,
Vishnu.R.Nair,
5th year Pharm.D,
National College of Pharmacy, Kerala, India.
Introduction to daily activities of clinical pharmacist.
Drug therapy monitoring,
Medication chart review
Clinical Progress
Pharmacist intervention
Detection and management of ADRs
A concise overview of pharmacoeconomics, health economics, various costs, various pharmacoeconomic study designs and its application in the field of medicine and drug development
Newer drugs approved by US-FDA - Rxvichu!!!RxVichuZ
This is my 22nd ppt............................
It contains HALF of the totl drugs approved by US-FDA for 2014
Consists of 20 drugs...out of 41
Do go through it.....and send ur reviews!
Regards,
Rxvichu-alwz4uh!
:)
Renal function tests - a deep insight by rxvichu!RxVichuZ
Hello friends...!
Exactly a year from today, i made my google slideshare account...and started publishing my ppts in it.....
Today, I am publishing my 25th ppt........
And the first ppt in CLINICAL PHARMACY!!
This is regarding RENAL FUNCTION TESTS......
Hope it may help anyone who refer this.
God bless :)
@rxvichu-alwz4uh! :) :)
Peptic ulcer disease a brief insight- by rxvichu!!!!RxVichuZ
Hello friends...............its me Vishnu................with my 14th ppt............................
This ppt is on PEPTIC ULCER DISEASE.................Based on therapeutic, pharmacological, and patient counselling point of view...........................
Done with great detail and incorporation of maximum information as possible....hope it helps the readers n viewers!!
Do post ur comments! and reviews!!!
Thank you!!!!
@rxvichu-alwz4uh!!
Local anaesthetics – a brief outlook by Rxvichu!!RxVichuZ
This is my 24th ppt!
Its on LOCAL ANESTHETICS.............It comprises varying drugs, their potencies, and other details....
Useful for 2nd year students.....and for reference!
Do check...n send ur reviews!
Thank you!
@rxvichualwz4uh!
:) :)
Seizure Disorders presentation for pathophysiology 2. presented on Sunday, may 10, 2015.
( Based on the type of behavior and brain activity, seizures are divided into two broad categories: generalized and partial (also called local or focal). Classifying the type of seizure helps doctors diagnose whether or not a patient has epilepsy.)
Fibroid uterus a deep insight - by rxvichu ;)RxVichuZ
Hello friends...............................
This is my FIRST PPT OUTSIDE PHARM.D SYLLABUS!!!!
This ppt is REGARDING FIBROID UTERUS, with a therapeutical & pathophysiological approach!!
Do go through....will surely be useful for students posted in OBG departments!
Regards,
@rxvichu-alwz4uh! :)
Hospital – its functions, types and organization- By rxvichu !!! :)RxVichuZ
Hello friends...........:)
This is my first ppt on HOSPITAL PHARMACY SUBJECT......
This ppt comprises:
a. DEFINITION OF HOSPITAL
b. FUNCTIONS OF HOSPITAL
c. CLASSIFICATION OF HOSPITAL
d. ORGANIZATION OF HOSPITAL.........
Hope u like the ppt! do send ur reviews!!!
@rxvichu-alwz4uh!! :)
The world’s population is ageing rapidly, and with it is coming to a significant increase in the number of
older people with dementia. This increase presents major challenges for the provision of healthcare
generally and for dementia care in particular, for as more people have dementia, there will be more
people exhibiting behavioural and psychological symptoms of dementia (BPSD).
BPSD exact a high price from both the patient and the caregiver in terms of the distress and disability
they cause if left untreated. BPSD is recognisable, understandable and treatable. The recognition and
appropriate management of BPSD are important factors in improving our care of dementia patients
and their caregivers,
On the occasion of National Epilepsy Day 2014, Dr. ES Krishnamoorthy introduced basic concepts of Epilepsy at the Epilepsy Knowledge Forum in Chennai organised by Neurokrish & Trimed and Sponsored Medall.
Definition, Medical and Nursing Management of the following Neurological Disorder-Cerebrovascular Disorders, Transient Ischemic Attack, Brain Attack, Cerebral Aneurysm, Subarachnoid Hemorrhage
Dementia is a broad category of brain diseases that cause a long term and often gradual decrease in the ability to think and remember such that a person's daily functioning is affected.
Dementia is acquired global impairment of intellectual, memory and personality but without impairment of consciousness.
This presentation deals with pathophysiology of Parkinson's Disease.
Important headings, including normal physiology, etiological factors and clinical manifestations have been elucidated.
This powerpoint, deals with HIV pathophysiology, signs and symptoms, mode of transmission and diagnostic parameters.
Purely based on clinical pharmacist perspective.
This presentation deals with buprenorphine drug profile, from a clinical pharmacist perspective.
Summarized version of drug, including chief ADRs, interactions, and patient and health-care professional counselling tips have been mentioned.
This PDF deals with important catchpoints regarding the use of 5-alpha reductase inhibitors, their safety and efficacy stats, and important counselling tips.
This PDF deals with important guidelines, with respect to usage of antibiotics. This PDF outlines the important strategies involved while using antibiotics, and important factors involving antibiotic selection.
This word document deals with summarized drug profile of cotrimoxazole. Important pharmacological headings, along with important counselling tips and drug catchpoints have also been elucidated.
This is my first word document, converted into pdf format!
This document deals with AMOXICILLIN drug profile in brief.
It includes significant pharmacological headings, including an additional heading, stating important catchpoints with respect to amoxicillin!
Food drug interactions with penicillins: by RxVichuZ!RxVichuZ
This is my 107th powerpoint...it deals with significant drug-food interactions when taking specific penicillins.
This is my first powerpoint that deals with drug interactions.
Do support!
Snake bite poisoning and its treatment by RxVichuZ!RxVichuZ
My 106th powerpoint...that deals with snake bite poisoning.
Different types of venomous snakes, their characteristics, envenomation features and treatment strategies have been explained in a summary.
Hope it is effective for the readers involved.
This powerpoint is a case presentation, that explains the case of ADCHF, with comorbidities, comprising HTN, CAD and DLP.
A summary on the recent advancements in HF management, along with justification of therapy provided, has been elucidated.
A note on home remedies and counselling tips has also been provided.
Directly acting antivirals and Visceral Leishmaniasis: A case reportRxVichuZ
This presentation deals with visceral leishmaniasis induced by directly acting antivirals in a patient with Hepatitis C infection.
Case details in summary, along with case report publication details have been summarized.
References have been provided below each slide.
...and this is my 100th powerpoint.....!!
Sincerely thanking everyone who have supported me in my journey till now :) :)
This powerpoint deals with drug mnemonics, easy to remember mnemonics, that can be helpful for easy memory of some aspects of Pharmacology!!
Happy reading!!
Acute coronary syndrome management by RxVichuZ! ;)RxVichuZ
This is my 99th powerpoint...
Deals with ACS(Acute coronary syndrome), its clinical features, and management strategies, based on standard guidelines and literatures.
RNTCP guidelines for tuberculosis management: Extended versionRxVichuZ
This presentation is an extension of the already made presentation before, that deals with RNTCP guidelines for some special aspects encountered during tuberculosis management, other than management of individual diagnoses alone.
Have a look!
Journal club presentation: by RxVichuZ!! ;)RxVichuZ
My 97th powerpoint... deals with the comparative study of efficacy of piperacillin-tazobactam, as compared to meropenem in the treatment of ESBL(Extended spectrum beta-lactamases) infections.
A summarized insight has been provided, using research article from JAMA.
PPI-INDUCED BICYTOPENIA: MATTER OF CONCERN by RxVichuZ! ;)RxVichuZ
This presentation deals with bicytopenia induced by proton pump inhibitors, that were reported and published as a Case Report by researchers from China.
References have been provided as a separate textbox under each slide, for extensive referencing into the same.
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insightRxVichuZ
This presentation deals with DPP-IV inhibitors, that are implicated for use in diabetes mellitus. Generalized pharmacology, including a precise insight into individual drugs have been elucidated.
Principles of cancer chemotherapy: a deep insight by RxVichuZ!RxVichuZ
This powerpoint deals with principles of cancer chemotherapy, that includes headings regarding cancer definition, its etiology, diagnostic measures and general considerations to be observed while initiating anti-cancer regimens in patients.
Sulfonylureas for Diabetes: A deep insightRxVichuZ
This powerpoint presentation solely deals with Sulfonylureas, that come under Insulin secretagogues. Their complete pharmacological profile, with pharmacovigilance parameters, important catchpoints and mnemonics have been explained.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Epilepsy and seizures a deep insight- by Rxvichu!!
1. EPILEPSY AND SEIZURES- A DEEP
INSIGHT
PRESENTED BY:
VISHNU.R.NAIR,
4TH YEAR PHARM.D,
NATIONAL COLLEGE OF PHARMACY,
KERALA UNIVERSITY OF HEALTH SCIENCES(KUHS),
2. INDEX/CONTENTSOFTHISPPT:
1. GENERAL ACKNOWLEDGEMENT
2. GENERALIZED TERMINOLOGIES
3. EPIDEMIOLOGY
4. TYPES OF EPILEPSIES{INCLUDING CLINICAL
MANIFESTATIONS}
5. ETIOLOGY OF EPILEPSY
6. PATHOPHYSIOLOGY OF EPILEPSY
7. RISK FACTORS FOR SEIZURES
8. DIAGNOSIS OF EPILEPSY
9. MANAGEMENT STRATEGIES FOR EPILEPSY
3. GENERAL ACKNOWLEDGEMENT :
TO THE ALMIGHTY , MY NEAR AND DEAR ONES… AND TO
ALL READERS WORLDWIDE!!!
THANKFUL TO ALL FOR UR SUPPORT, GUIDANCE AND
ENCOURAGEMENT………………
ITS BEEN A REALLY HARD JOB WORKING ON THIS
PPT…………………
HOPE U LIKE IT!!
HAPPY READING!!!
4. GENERALIZED TERMINOLOGIES :
1. SEIZURE:
“PHENOMENON, characterized by an EXCESSIVE, HYPERSYNCHRONOUS
DISCHARGE of CORTICAL NEURONAL ACTIVITY, (measured by EEG), featured by
DISTURBANCES in CONSCIOUSNESS, SENSORY MOTOR SYSTEMS, SUBJECTIVE
WELL-BEING and OBJECTIVE BEHAVIOUR…………………”
2. EPILEPSY:
“CHRONIC SEIZURE DISORDER/ GROUP OF DISORDERS, characterized by SEIZURES,
that usually occur UNPREDICTABLY, in the ABSENCE of a SUBSTANTIAL PROVOKING
FACTOR…………….”
3. CONVULSION:
“VIOLENT, INVOLUNTARY CONTRACTIONS of VOLUNTARY MUSCLES, which may/
may not be present in epilepsy/ seizure disorder………..............”
5. EPIDEMIOLOGY OF EPILEPSY :
- Higher risk observed in extremes of age
- Prevalence in European countries is 0.5%
- Prevalence in developing countries is higher, due to parasitic illnesses like
CYSTICERCOSIS
- Around 50 million people worldwide have epilepsy
- Epilepsy responds to treatment in 70% cases
- 75% people in developing countries do not get required anti-epileptic
treatment…………………..
6. TYPES OF EPILEPSIES (INCLUDING
CLINICAL MANIFESTATIONS) :
Based on INTERNATIONAL LEAGUE AGAINST EPILEPSY(ILAE)
classification:
1. PARTIAL SEIZURES (FOCAL SEIZURES)
2. GENERALIZED SEIZURES ………………………………………
7. 1. PARTIAL SEIZURES (FOCAL SEIZURES):
- Most common seizure type
- Localized to a neuronal system, limited to PART OF 1 CEREBRAL HEMISPHERE
- Types include:
A. SIMPLE PARTIAL SEIZURES:
- Not associated with loss of consciousness
- Associated with:
i. MOTOR SIGNS (Convulsive jerking, lip smacking)
ii. SENSORY & SOMATOSENSORY SIGNS (Paresthesias, auras)
iii. AUTONOMIC SIGNS (Sweating, flushing)
iv. BEHAVIOURAL MANIFESTATIONS (Dysphasia, structured hallucinations)
8. B. COMPLEX PARTIAL SEIZURES:
- Associated with IMPAIRED CONSCIOUSNESS
- Impairment precedes/ follows seizures
- Associated with:
i. Purposeless behavior
ii. Glassy stare
iii. Aimless walking
iv. Hallucinations (visual, auditory)
v. Aggressive behaviour……………………………….
9. 2. GENERALIZED SEIZURES:
- Diffuse seizures
- Affect BOTH CEREBRAL HEMISPHERES
- Types include:
A. IDIOPATHIC EPILEPSIES:
- Age related onset
- Also congenital (genetic origin)
B. SYMPTOMATIC EPILEPSIES:
- Aftermath of a DOCUMENTED UNDERLYING CNS DISORDER
C. CRYPTOGENIC EPILEPSY:
- Cause unknown
- Presumed to be age- related
10. Manifestations of generalized seizures include:
A. ABSENCE SEIZURES:
- Also known as ‘PETIT MAL’ seizures
- Alterations of consciousness, lasting 10-30 mins. Occurs
- Associated with:
a. Staring, with occasional eye-blinking
b. Enuresis
B. MYOCLONIC SEIZURES:
- Also known as ‘BILATERAL MASSIVE EPILEPTIC MYOCLONUS’
- Associated with INCVOLUNTARY, RHYTHMIC JERKING of FACIAL, LIMB/ TRUNK
MUSCLES
C. CLONIC SEIZURES:
- Associated with SUSTAINED MUSCLE CONTRACTIONS, alternating with
RELAXATION
11. D. TONIC SEIZURES:
- Associated with SUSTAINED MUSCLE CONTRACTIONS (Stiffening)
E. GENERALIZED TONIC-CLONIC SEIZURES (GTCS):
- Also known as ‘GRAND MAL’ seizures
- Causes sudden loss of consciousness
- Individual becomes rigid and falls to the ground
- Interrupted respirations
- Extended legs
- Lasts for 1 min.
- Rapid bilateral muscle jerking
- Heavy salivation, tongue biting, headache, confusion
- In some cases, GRAND MAL seizures occurs repeatedly, with no recovery of consciousness
between attacks, leading to state known as ‘STATUS EPILEPTICUS’………………..
12. F. ATONIC SEIZURES:
- Also known as ‘DROP ATTACKS’
- Sudden loss of postural tone individual falls to the ground
- Occurs mainly in children…………………………………..
13. ETIOLOGY OF EPILEPSY :
Mainly we will see the causes of:
A. FOCAL SEIZURES
B. GENERALIZED SEIZURES…………………………..
14. 1. CAUSES OF FOCAL SEIZURES:
Include:
A. IDIOPATHIC REASONS:
- Benign ROLANDIC epilepsy of childhood (Discovered by Italian Anatomist Luigi Rolando)
- Benign OCCIPITAL epilepsy of childhood
B. GENETIC REASONS:
- Tuberous sclerosis (characterized by tiny benign tumours {angiofibromas} on the face, skin, and
abnormalities of kidney, brain and heart)
- Autosomal dominant frontal lobe epilepsy
- Autosomal dominant partial epilepsy with auditory features (ADPEAF)
- Von Hippel-Lindau disease (characterized by hemangioblastomas {benign blood vessel tumours } in
brain, spinal cord, retina; kidney cysts & cancer and pheochoromocytomas}
- Neurofibromatosis (causes tumours to grow on nerves and inhibits neural growth)
- Cerebral migration abnormalities
15. C. INFANTILE HEMIPLEGIA (acute hemiparesis, that occurs in infancy, caused
by vascular accidents, like cerebral infarction or thrombosis)
D. DYSEMBRYONIC CAUSES:
- Cortical dysgenesis
- Sturge-Weber syndrome (mainly affects the skin, featured by ‘port wine stain birthmark’;
also known as ‘Encephalotrigeminal angiomatosis’)
E. MESIAL TEMPORAL SEIZURES:
- Associated with febrile convulsions
F. CEREBROVASCULAR DISEASES:
- Intracerebral hemorrhage
- Cerebral infarction
- Arteriovenous malformation
- Cavernous hemangioma (occurs on body surface, as red or purplish, blood filled lakes/
channels)
16. G. PRIMARY AND SECONDARY TUMOURS
H. TRAUMA (including neurosurgery)
I. INFECTIVE CAUSES:
- Cerebral abscess (pyogenic) - Toxoplasmosis - Cysticercosis - Tuberculoma
- Subdural empyema - Encephalitis - HIV infections
J. INFLAMMATORY CAUSES:
- Sarcoidosis - Vasculitis………………………..
17. 2. CAUSES OF GENERALIZED SEIZURES :
Includes:
A. GENETICS:
- Inborn metabolism errors - Storage diseases - Phacomatoses (Tuberous
sclerosis)
B. CEREBRAL BIRTH INJURY
C. HYDROCEPHALUS
D. CEREBRAL ANOXIA
E. ALCOHOL WITHDRAWAL
F. TOXINS:
- Organophosphates (SARIN)
- Heavy metals (LEAD, TIN)
19. I. INFECTIVE CAUSES:
- Post- infective encephalopathy
- Meningitis
J. INFLAMMATORY CAUSES:
- Multiple sclerosis
- SLE
K. DIFFUSE DEGENERATIVE DISEASES:
- Alzheimer’s disease
- CREUTZFELDT- JAKOB DISEASE (Degenerative, invariably fatal brain disorder,
associated with failing memory ,behaviour changes, weakness of extremities, mental
deterioration and coma)……………………………..
20. PATHOPHYSIOLOGY OF EPILEPSY
:1. Neurons are inter-connected in a complex network
2. Each individual neuron linked via synapses with hundreds of others
3. Neurons discharge electrical current neurotransmitters are released at synaptic levels
permits inter- communication
4. Neurotransmitters are of 2 types:
a. INHIBITORY NEUROTRANSMITTER (GABA):
- GABA (Gamma amino butyric acid ) acts on ion channels increases chloride inflow
decreases chances of action potential formation
b. EXCITATORY NEUROTRANSMITTER ( ASPARTATE, GLUTAMATE):
- Above agents allow sodium and calcium influx paves way for action potential
formation
5. In this manner, information is conveyed, transmitted and processed throughout the CNS
6. Imbalance between above excitation and inhibition seizures occur
21. 7. A normal neuron discharges repetitively at LOW BASELINE FREQUENCIES
8. If neurons are damaged, injured/ suffer a chemical/ metabolic insult changes in discharge
pattern develops
9. During epilepsy regular low frequency discharges are replaced by BURSTS of HIGH
FREQUENCY DISCHARGES followed by periods of INACTIVITY
10. A single neuron discharging in an abnormal manner is usually not clinically significant
11. When a WHOLE POPULATION of NEURONS DISCHARGE SYNCHRONOUSLY in an
ABNORMAL MANNER EPILEPTIC SEIZURE IS PRECIPITATED
12. This abnormal discharge may remain LOCALIZED/ it may SPREAD TO ADJACENT
AREAS, RECRUITING MORE NEURONS as it EXPANDS…………………………….
22. RISK FACTORS FOR EPILEPSIES :
1. Sleep deprivation
2. Missed doses of anti-epileptic drugs(AEDs) in treated patients
3. Alcohol withdrawals
4. Recreational drug misuse
5. Physical and mental exhaustion
6. Flickering lights (includes TV, computer screens; comes under generalized epilepsy
syndrome)
7. Intercurrent infections
8. Metabolic disturbances
9. UNCOMMON REASONS:
- Loud noises
- Very hot baths…………………………………
23. DIAGNOSIS OF EPILEPSIES :
Based on the following criteriae:
1. TO CHECK THE LOCATION OF EPILEPTIC
ORIGIN:
- Standard EEG
- Sleep EEG
- EEG, with special electrodes
2. TO CHECK FOR STRUCTURAL LESIONS:
- CT SCAN - MRI SCAN
3. FOR METABOLIC DISORDER DIAGNOSIS:
- Urea and electrolytes - LFTs
- Blood glucose levels - Serum calcium and magnesium levels
24. 4. FOR INFLAMMATORY/ INFECTIVE DISORDER
DIAGNOSIS:
- CBC - ESR - CRP TEST - CHEST XRAY
- SEROLOGY FOR SYPHILIS, HIV, COLLAGEN DISEASE
- CSF EXAMINATION
5. FOR CONFIRMING ATTACKS TO BE OF EPILEPTIC
ORIGIN:
- Ambulatory EEG - Video telemetry
6. BRAIN IMAGING:
Indicated for:
- Epilepsy starting after 16 yrs. of age
- Seizures, with clinical focal features
- EEG, showing a focal seizure source
25. MANAGEMENT OF EPILEPSY :
Includes:
1. GOALS OF THERAPY
2. GENERAL GUIDELINES FOR ANTICONVULSANT
THERAPY
3. PHARMACOTHERAPY
4. GUIDELINES FOR CHOICE OF ANTI-EPILEPTIC
DRUGS(AEDs)
5. NON-PHARMACOTHERAPY/ PATIENT- COUNSELLING
TIPS+ HOME REMEDIES FOR EPILEPSY
26. 1. GOALS OF THERAPY :
1. To control and reduce SEIZURE FREQUENCY
2. To focus on MINIMUM POSSIBLE DOSAGE OF AEDs
3. To minimize ADRs associated with therapy
4. To ensure PATIENT MEDICATION COMPLIANCE
5. To ensure that person lives a normal life as far as possible
6. To balance COMPLETE SUPPRESSION of SEIZURES against ADR TOLERABILITY
7. To reduce MORBIDITY and MORTALITY
8. To improve QUALITY OF LIFE(QOL)………………………………..
27. 2. GENERAL GUIDELINES FOR
ANTICONVULSANT THERAPY :
1. Start with 1 FIRST LINE DRUG
2. Start with a low dose gradually increase dose until effective control of seizures is
achieved/ ADRs develop
3. Optimize compliance (use minimum no. of doses/ day)
4. If 1st line drug fails (seizures continue/ ADRs develop) start 2nd (1st line drug) , followed
(if possible) , by gradual withdrawal of the drug presently being used
5. If 2nd line drug fails (due to above reasons) start 2nd line drug, in combination with
preferred 1st line drug at maximum tolerated doses (keep in mind possible interactions)
6. If above combination fails (due to above reasons) replace 2nd line drug with alternative
2nd line drug
28. 7. If above combination fails (due to above reasons) check compliance & reconsider
diagnosis, based on the following criteriae:
a. If the events are seizures/ not
b. Presence absence of occult lesions
c. Treatment compliance/ alcohol/ drugs confounding responses
8. Consider alternative, non-drug treatments, like:
a. Epilepsy surgery
b. Vagal nerve stimulation
9. Use minimum number of drugs in combination at any one time………………………….
29. 3. PHARMACOTHERAPY :
A. BARBITURATES :
Include:
I. PHENOBARBITONE (LUMINAL):
- Drug has 3 actions:
a. Drug depresses sensory, motor cortex and cerebellum
b. Drug acts on GABA(A) receptors increases synaptic inhibition increases seizure
threshold and decreases spread of seizure activity from a seizure focus
c. Drug inhibits CALCIUM channels decreases excitatory transmitter release
- ADR :
a. Sedation c. Headache
b. Respiratory depression (when given i.v)
30. - DRUG INTERACTION:
a. Phenobarbital + oral contraceptives decreased efficacy of latter
- USES:
a. Febrile convulsions (8 mg/kg/day; child)
b. GTC c. Neonatal seizures d. Status Epilepticus (SE)
B. DEOXYBARBITURATES :
Includes:
I. PRIMIDONE (MYSOLINE):
- MOA:
Drug enters body metabolized by liver to PHENOBARBITONE Shows remaining effects
- ADR:
a. STEVEN-JOHNSON SYNDROME (SJS)
b. Hypotension
c. Hepatitis
31. - DRUG INTERACTION:
a. BZDs + Drug increased sedation
- USES:
A. GTCS (250-500 mg BD)
B. Partial epilepsy
C. HYDANTOINS :
Includes:
A. PHENYTOIN (BARBITOIN):
- Drug has 3 actions:
i. Drug promotes sodium efflux/ decreased sodium influx from membranes in motor
cortex neurons
ii. Drug stabilizes neuronal membranes
iii. Drug slows conduction velocity
32. - ADR:
i. Gingival hyperplasia
ii. Hirsutism
iii. Megaloblastic anemia
iv. Diabetes mellitus
v. FETAL HYDANTOIN SYNDROME (Drug used in pregnancy causes hare lips,
microcephaly in neonates etc)
- DRUG INTERACTIONS:
a. Drug + Pyridoxine(in high dose) decreased levels of phenytoin
- USES:
a. Tonic clonic seizures
b. SE (10-15 mg/kg i.v/ infusion)
33. B. FOSPHENYTOIN (FOSPHEN):
- MOA:
Drug converted to PHENYTOIN after injection shows actions of PHENYTOIN
- ADR:
a. Hypersensitivity b. SJS c. Hepatotoxicity
- DRUG INTERACTIONS:
a. Drug + CBZ(Carbamazepine) decreased CBZ efficacy
- USES:
a. Seizures, associated with NEUROSURGERY/ HEAD INJURY
b. SE (20 mg/kg i.v)………….
34. D. IMINOSTILBENES :
Includes:
A. CARBAMAZEPINE (CARBATOL):
- Drug shows 2 actions:
i. Drug stabilizes inactivated state of sodium channels makes neurons less excitable
ii. Drug decreases activity of NUCLEUS VENTRALIS of thalamus / synaptic
transmission associated with neuronal discharge
- ADR:
a. SJS b. Arrhythmia c. CHF
- DRUG INTERACTIONS:
a. Drug + warfarin decreased anticoagulant effect
- USES :
a. Trigeminal neuralgia c. Epilepsy (200-400 mg TDS)
b. Bipolar disorder
35. B. OXCARBAZEPINE (CARBOX):
- Drug shows 5 actions:
i. Drug blocks sodium channels stabilizes neuronal membranes
ii. Drug inhibits repetitive firing
iii. Drug reduces synaptic impulse propagation
iv. Drug increases potassium conductance
v. Drug modulates activity of high voltage activated calcium channels
- ADR:
a. SJS b. Hepatitis c. Pancreatitis
- DRUG INTERACTION:
a. Furosemide + drug increased risk of HYPONATREMIA
- USES :
a. Partial seizures , with/ without secondary generalization (in adults: 0.6-2.4 g/day, in divided
doses)……………………
36. E. SUCCINIMIDES:
Includes:
A. ETHOSUXIMIDE (ZARONTIN):
- Drug shows 2 actions:
i. Drug depresses nerve transmission in motor cortex
ii. Drug increases convulsive stimuli threshold in CNS
- ADR:
a. GI disturbances b. Dizziness
- DRUG INTERACTION:
a. Drug + sodium oxybate pharmacodynamic synergism increased toxicity of each
other additive CNS depression
- USE:
a. Absence seizures : 500 mg P/O QID…………………….
37. F. ALIPHATIC CARBOXYLIC ACIDS:
Includes:
I. VALPROIC ACID (VALPROL):
- Drug shows 3 actions:
i. Drug increases GABA levels in brain
ii. Drug increases / mimics action of GABA at postsynaptic receptor sites
iii. Drug inhibits sodium and calcium channels
- ADR:
a. SJS b. Pancreatitis c. Thrombocytopenia
- DRUG INTERACTION:
a. Drug + Chlorpromazine severe HEPATOTOXICITY
- USES:
a. Complex partial seizures (For adults: max. 60 mg/kg/day)
b. Simple and complex absence seizures…………………..
38. II. DIVALPROEX (DIVAA):
- MOA : Same as that of SODIUM VALPROATE
- ADR:
a. Increased bleeding time
b. Encephalopathy
c. Dementia
- DRUG INTERACTION :
a. Drug + cholestyramine decreased levels of divalproex
- USES :
a. Complex partial seizures (max.: 60 mg/kg/day)
b. Mania
c. Migraine prophylaxis
d. Simple and complex absence seizures………………………………
39. G. BENZODIAZEPINES :
Includes:
I. CLONAZEPAM (CLONA):
- Long acting BZD
- Drug shows 3 actions:
a. Drug increases presynaptic GABA inhibition
b. Drug decreases monosynaptic and polysynaptic reflexes
c. Drug facilitates GABA neurotransmission and other inhibitory neurotransmitters
suppresses muscle contractions
- ADR:
a. Blood disorders b. Increased LFTs c. Respiratory depression
- DRUG INTERACTION:
a. Amiodarone + drug increased drug toxicity
40. - USES:
a. Panic disorder
b. Seizure disorders (For adult: up to 1.5 g , in 3 divided doses)
c. SE
II. CLOBAZAM (CLOBA):
- 1,5- BENZODIAZEPINE (Contrary to others)
- MOA:
Drug binds to GABA(A) receptor potentiates GABA- ergic neurotransmission
- ADR:
a. Hypotension b. Respiratory depression c. Jaundice
- DRUG INTERACTION:
a. CBZ + Clobazam decreased drug levels
b. Alcohol + Clobazam increased drug levels
41. III. DIAZEPAM (DIZEP):
- Drug shows 2 actions:
a. Drug modulates postsynaptic effects of GABA(A) transmission results in an
increase in presynaptic inhibition
b. Drug acts on part of limbic system, thalamus and hypothalamus induces CALMING
EFFECT
- ADR:
a. Respiratory depression
b. Hypotension
c. Jaundice
- DRUG INTERACTION:
a. Hormonal contraceptives + Drug increased drug effects increased incidence of
BREATH-THROUGH BLEEDING
42. - USES:
a. STATUS EPILEPTICUS (Adult: 5-10 mg every 5-10 mins. ; maximum 30 mg.)
b. Anxiety
c. Conscious sedation for procedures
d. Ethanol withdrawal
e. Insomnia associated with anxiety
f. Muscle spasm with tetanus
g. Night terrors
h. Sedation
i. Skeletal muscle relaxation
j. Sleep walking………………………………..
43. IV. LORAZEPAM (LOPEZ):
- Short onset of effect
- Long half-life
- Drug shows 2 actions:
a. Drug increases action of GABA
b. Drug depresses all levels of CNS, including lumbar and reticular formation
- ADR:
a. Respiratory depression b. Hypotension c. Jaundice
- DRUG INTERACTIONS:
a. Loxapine + drug increased respiratory depression
b. Zidovudine + drug increased headache
44. - USES:
a. Antiemetic (adjuvant therapy)
b. Acute anxiety
c. Insomnia associated with anxiety
d. Panic disorder
e. Pre-operative medication
f. Sedation
g. SE (For adult: 4 mg; repeat once after 10 mins, if necessary)………………………..
45. H. PHENYLTRIAZINES:
Includes:
LAMOTRIGINE (LAMORIN):
- Drug shows 2 actions:
a. Drug inhibits release of excitatory amino acids (glutamate)
b. Drug inhibits voltage sensitive sodium channels stabilizes neuronal membranes
- ADR:
a. SJS b. DIC c. Lymphadenopathy
- DRUG INTERACTION:
a. Drug + Phenytoin/Phenobarbital decreases levels of drug
- USES:
a. Bipolar disorder
b. GTC( For adult: 25 mg/day for initial 14 days then increase dose to 50 mg/day for next
14 days then increase dose to 50-100 mg/day for next 7-14 days)……………………..
46. I. CYCLIC GABA ANALOGUES:
Includes:
A. GABAPENTIN (GABAPENTIN):
- Structurally related to GABA, but has no effect on GABA binding, uptake/ degradation
- MOA:
Drug modulates voltage sensitive calcium channels decreases entry of calcium into
presynaptic neurons decreases glutamate release decreases neuronal excitability
- ADR :
a. SJS b. ARF c. Hepatitis
- DRUG INTERACTION:
a. Drug + phenytoin/antacids decreased levels of latter
47. - USES:
a. Diabetic neuropathy
b. Focal seizures, with/ without secondary generalization (For child: 12-18 yrs 300 mg
TID/ 0.9-3.6g/day ,in 3 divided doses)
c. Restless legs syndrome
d. Post- therpetic neuralgia / neuropathic pain………………
B. PREGABALIN (PREGALIN):
- Drug shows 2 actions:
i. Drug binds to a subunit of voltage gated calcium channels in CNS remaining same
as GABAPENTIN
ii. Does not affect sodium channels
- ADR:
a. Primary AV block b. CHF c. SJS
48. - DRUG INTERACTIONS:
a. Drug + Lorazepam/ alcohol increased efficacy of latter
- USES:
a. Partial seizures, with/ without secondary generalization (50-300 mg/day, in 2-3 divided
doses, for adults; maximum: 600 mg/day)
b. Anxiety
c. Peripheral and central neuropathic pain
d. Fibromyalgia……………………………..
49. J. NEWER DRUGS:
Include:
I .TOPIRAMATE
II.ZONISAMIDE
III. LEVETIRACETAM
IV. VIGABATRIN
V. TIAGABINE
VI. LACOSAMIDE
VII. FELBAMATE
VIII. RUFINAMIDE
IX. STIRIPENTOL
X. ESLICARBAZEPINE ACETATE
XI. PERAMPANEL…………………………………..
50. I. TOPIRAMATE (TOPIRATE):
- CLASS: SULFAMATE SUBSTITUTED DERIVATIVE
- Drug shows 2 actions:
a. Drug inhibits neuronal voltage dependent sodium channels
b. Drug enhances activity of GABA
- ADR:
a. SJS b. Thrombocytopenia c. Toxic epidermal necrolysis(TEN)
- DRUG INTERACTION:
a. Zonisamide+ drug increased risk of renal calculi
- USES:
a. Epilepsy (200-1000 mg/day)
b. Migraine prophylaxis
c. Partial seizures……………………………….
51. II. ZONISAMIDE (ZONICARE):
- CLASS: SULFONAMIDE DERIVATIVE (Benzisoxazole compound)
- Drug shows 3 actions:
a. Drug acts at sodium and calcium channels stabilizes neuronal membranes
b. Does not affect GABA activity
c. More active against TONIC PHASE than against CLONIC PHASE
- ADR:
a. SJS b. TEN c. Rhabdomyolysis
- DRUG INTERACTION:
a. CBZ+ Zonisamide decreased level of Zonisamide (by affecting CYP3A4 metabolism)
- USES:
a. Partial seizures, with/ without secondary generalization (300-500 mg/ day; in 1-2 divided
doses)……………………………………..
52. III. LEVETIRACETAM (LEVACETAM):
- CLASS: PYRROLIDINE DERIVATIVE
- Drug shows 3 actions:
a. Drug inhibits voltage dependent N-TYPE CALCIUM CHANNELS
b. Drug binds to synaptic proteins modulate neurotransmitter release
c. Drug displaces negative modulators facilitates GABA- ergic inhibitory transmission
- DRUG INTERACTION:
a. CBZ + Drug CBZ toxicity occurs
- ADR:
a. Thrombocytopenia b. Pancreatitis c. Hepatic dysfunction
- USES:
a. GTC (Max: 1.5 g BID; For adults)
b. Myoclonic seizures
c. Partial seizures, with or without secondary generalization………………….
53. IV. VIGABATRIN (SABRIL):
- CLASS: GAMMA-VINYL GABA DERIVATIVE
- MOA:
Drug irreversibly inhibits GABA-transaminase increases GABA levels in brain
- ADR:
a. Weight gain in children (47%)
b. Permanent bilateral concentric visual field constriction (>30%)
c. Fatigue (28%)
- DRUG INTERACTION:
a. Drug + CLOBAZAM Increased sedation, respiratory depression
- USES:
a. Complex seizures (1.5 g BID)
b. Partial seizures
c. Infantile spasms
d. Refractory complex seizures………………………….
54. V. TIAGABINE (GABITRIL):
- CLASS: GABA REUPTAKE INHIBITOR
- MOA:
drug blocks GABA reuptake by presynaptic neuron increases its activity in nervous
system
- ADR:
a. Dizziness (26-30%)
b. Asthenia (16-20%)
c. Somnolence (16-20%)
- DRUG INTERACTION:
a. Drug + Clobazam increased sedation/ respiratory depression
- USES:
a. Partial seizures (with hepatic enzyme inducing anticonvulsants)
b. Partial seizures (without hepatic enzyme inducing anticonvulsants; 12-22 mg/day , divided
in 2-3 doses)…………………………………
55. VI. LACOSAMIDE (LACOSAM):
- CLASS : HOMOSERINAMIDE DERIVATIVE; FUNTIONAL AMINO ACID
- Drug shows 2 actions:
a. Drug slowly inactivates voltage gated sodium channels
b. Drug binds to collapsin response mediator protein-2 (CRMP-2); a phosphoprotein;
expressed mainly in nervous system modulates neuronal differentiation and axonal
outgrowth
- ADR:
a. Dizziness (31%) d. Atrial fibrillation
b. Diplopia (11%) e. Atrial flutter
c. Headache (11%) f. Suicidal ideation
- DRUG INTERACTION:
a. Drug + anti- arrhythmics enhanced PR-prolongation
- USES:
a. Neuropathic pain b. Partial seizures (200-400 mg/day)…….
56. VII. FELBAMATE (FELBATOL):
- CLASS : CARBAMATE DERIVATIVE
- Drug shows 2 actions:
a. Drug positive modulator of GABA(A) receptor
b. Drug blocks NMDA receptors (NR2B subunit)
- ADR:
a. Anorexia
b. Liver failure
c. Aplastic anemia
- DRUG INTERACTION:
a. Felbamate + clopidogrel decreased effects of clopidogrel
- USES:
a. Partial seizures, with/ without secondary generalization (Adults: 1,200 mg Q6H/Q8H)
b. Partial/ Generalized seizures , associated with LENNOX-GASTAUT SYNDROME …….
57. VIII. RUFINAMIDE (BANZEL):
- CLASS : TRIAZOLE DERIVATIVE
- MOA:
Drug modulates activity of sodium channels prolongs their inactive state limits
repetitive firing of sodium dependent action potentials anticonvulsant effect
- ADR:
a. Diplopia
b. SJS
c. Dizziness
- DRUG INTERACTION :
a. Rufinamide + alprazolam decreased levels/ effects of latter
- USE:
a. LENNOX-GASTAUT SYNDROME (3,200 mg/day maximum, in 2 divided
doses)……………………………..
58. IX. STIRIPENTOL (DIACOMIT):
- CLASS: AROMATIC ALLYLIC ALCOHOLS
- Drug shows 5 actions:
a. Drug increases GABA transmission
b. Drug increases duration of opening of GABA(A) receptor channels in hippocampal
areas enhances central GABA transmission
c. Drug increases GABA levels in brain tissues by interfering with its uptake &
metabolism
d. Drug inhibits LACTATE DEHYDROGENASE Makes neurons less prone to fire
action potentials
e. Drug improves effectiveness of other anti-convulsants……………
- ADR:
a. Hyperkinesia
b. Drowsiness
c. Ataxia
59. - DRUG INTERACTION:
a. Drug + CBZ/ Phenobarbital increased efficacy/ potency of latter
- USES:
a. DRAVET SYNDROME (Along with sodium valproate and Clobazam; 50 mg/kg/day)
b. Epilepsy in infancy
c. Refractory childhood epilepsy( in combination with CBZ)………….
X. ESLICARBAZEPINE ACETATE (ESLIZEN):
- CLASS : DIBENZAPINE CARBOXAMIDE DERIVATIVE
- Drug shows 3 actions:
a. PRODRUG activated to ESLICARBAZEPINE/ S-LICARBAZEPINE (Major active
metabolite of OXCARBAZEPINE) Blocks sodium channels inhibits repetitive firing
decreases synaptic impulse propagation stabilizes neuronal membranes
b. Drug increases potassium conductance
c. Drug modulates activity of high voltage gated activated calcium channels
60. - ADR:
a. Blurred vision
b. HTN
c. Peripheral edema
- DRUG INTERACTION:
a. Drug + Phenytoin/ Barbiturates decreased drug levels
- USE:
a. Partial onset seizures (for adult: 400 mg/day; for 7 days)……………….
61. XI. PERAMPANEL (FYCOMPA):
- CLASS : NON-COMPETITIVE AMPA RECEPTOR ANTAGONIST)
- MOA:
Drug non- competitively blocks ALPHA-AMINO-3-HYDROXY-5-METHYL-4-
ISOXAZOLEPROPIONIC ACID (AMPA ) glutamate receptor on post synaptic neurons
decreased glutamate activity decreases neurological disorders causes by glutamate over-
excitation
- ADR:
a. Dizziness (16-43%)
b. Somnolence (9-18%)
c. Suicidal ideation (notorious)
- DRUG INTERACTION:
a. Drug +CBZ Decreased perampanel effectiveness
- USES:
a. Partial onset seizures (8-12 mg/day) b. Tonic clonic seizures……………….
62. 4. GUIDELINES FOR CHOICE OF
ANTI-EPILEPTIC DRUGS :
A. FOR FOCAL ONSET AND / SECONDARY GTCS:
- IST LINE DRUG : LAMOTRIGINE
- 2ND LINE DRUGS : CBZ, LEVETIRACETAM, VALPROIC ACID, TOPIRAMATE ,
ZONISAMIDE, LACOSAMIDE
- 3RD LINE DRUGS: CLOBAZAM, GABAPENTIN, OXCARBAZEPINE,
BARBITURATES , PHENYTOIN, PREGABALIN, PRIMIDONE, TIAGABINE…..
B. FOR GTCS:
- 1ST LINE DRUGS : VALPROIC ACID, LEVETIRACETAM
- 2ND LINE DRUGS : LAMOTRIGINE, TOPIRAMATE, ZONISAMIDE
- 3RD LINE DRUGS : CBZ, PHENYTOIN, PRIMIDONE, BARBITURATES……………
63. C. FOR ABSENCE SEIZURES :
- 1ST LINE DRUG : ETHOSUXIMIDE
- 2ND LINE DRUGS : SODIUM VALPROATE
- 3RD LINE DRUGS : LAMOTRIGINE, CLONAZEPAM……………
D. FOR MYOCLONIC SEIZURES:
- 1ST LINE DRUG: SODIUM VALPROATE
- 2ND LINE DRUGS : LEVETIRACETAM, CLONAZEPAM
- 3RD LINE DRUGS : LAMOTRIGINE, PHENOBARBITAL………………………
64. 5. NON-
PHARMACOTHERAPY/PATIENT-
COUNSELLING TIPS +HOME
REMEDIES FOR EPILEPSY :1. AVOID ACTIVITIES, WHERE PATIENTS MAY PLACE
THEMSELVES/ OTHERS AT RISK, IF THEY HAVE A
SEIZURE (APPLIES AT WORK, HOME/ AT LEISURE)
2. TAKE ONLY SHALLOW BATHS/ SHOWERS
3. AVOID PROLONGED CYCLE JOURNEYS ,UNLESS
REASONABLE FREEDOM FROM SEIZURES HAS BEEN
ACHIEVED
4. ACTIVITIES, THAT REQUIRE PROLONGED PROXIMITY TO
WATER (FISHING SWIMMINING,BOATING ) SHOULD BE
65. 5. RECONGIZED MORTALITY OF EPILEPSY SHOULD BE
DISCUSSED AT THE TIME OF DIAGNOSIS, AIMED AT
MOTIVATING THE PATIENT, TO ADAPT TO HABITS AND
LIFESTYLE, TO OPTIMIZE EPILEPSY CONTROL
6. COCONUT OIL:
- Highly effective
- Fatty acids (medium chain triglycerides) in oil possess therapeutic effects on brain cells
- Oil supplies energy for brain cells relieves epilepsy symptoms
- Use 1-3 tsp of EXTRA VIRGIN COCONUT OIL (3 times a day)
7. EPSOM SALT:
- EPSOM SALT Contains magnesium sulphate changes psychochemical cell
relationships in the brain reduces frequency of seizures and convulsions
- Use in the form of:
a. Epsom salt bath (2-3 times/ week)
b. Add half tsp of salt to orange juice / water drink every morning
66. 8. LIME:
- Popular Ayurvedic remedy
- Lime helps improve blood circulation to brain
- Also normalizes excess calcium that may hamper brain functionality
- Use in the form of:
a. (2 tsp. lime juice + half tsp. baking soda + water) drink daily before going to bed
b. Apply lime juice on head massage thoroughly for a few mins. do daily before taking a
shower
9. GARLIC:
- Garlic possesses ANTIOXIDANT, ANTISPASMODIC & ANTI-INFLAMMATORY
PROPERTIES Promotes proper functioning of nervous, along with destruction of harmful free
radicals in body prevents seizures and related symptoms
- Use it in the form of:
a. Mix half cup of milk + half cup water boil add 4-5 crushed garlic cloves strain and drink it
once daily
b. Garlic supplements (under doctor advice)
67. 10. PASSIONFLOWER :
- Herb contains CHRYSIN increases GABA amount in brain decreases seizures frequency,
anxiety
- Use it in the form of :
a. CAPSULE, TABLET FORMS
b. HERBAL TEA (1-2 CUPS)
- Avoid in pregnancy/ lactation
11. WINTER MELON:
- Also known as ‘ASH GOURD’
- Popular Ayurvedic remedy
- Vegetable helps keeps nervous system healthy
- Also ensures smooth functioning of brain cells
- Use in the form of:
a. Half glass winter melon juice + little sugar drink in the morning on empty stomach
b. Extract juice of crushed winter melon add 1-2 tsp licorice powder to it mix well drink this
solution once daily
68. 12. EXERCISE :
- Improves fitness, energy and mood reduces seizures and impact of epilepsy on one’s life
- Exercise releases positive feeling hormones into brain increases oxygen flow to brain
- Go for warm up/ stretching exercises
- Walk for 45 mins. , 4 times a week
- Drink water before and after exercise to prevent dehydration
- Stop and rest if you are feeling tired
13. YOGA:
- Alleviates stress
- Induces relaxation
- Combination of DEEP BREATHING, PHYSICAL POSTURES AND MEDITATION
Controls seizures and reduces other epilepsy symptoms
- Best yoga poses for epilepsy are:
a. Balasana(child’s pose) b. Nadi shodhana(alternate nostril breathing)
c. Kapotasana (pigeon pose) d. Sirsasana (headstand)
69. 14. VITAMINS:
- Certain vitamins control neurons that cause seizures and anxiety disorders
- Consume the following Vitamin supplements after doctor consultation:
a. Vitamin E b. Vitamin B6 c. Vitamin B1 d. Vitamin D e. Vitamin B12
15. ACCUPUNCTURE:
- “Phenomenon of applying pressure to specific points on the body, by using fine needles”
- Acupuncture restores flow of energy throughout the body alters brain activity reduces
seizures
16. COUNSELLING TIPS IN PREGNANCY:
- Start FOLIC ACID 5 mg daily for 2 months before conception , to reduce risk of AED induced fetal
abnormalities
- Since some AEDs are associated with hemorrhage risk, give oral Vitamin K 20 mg daily to mother
during last month of pregnancy, and Vitamin K (1 mg i.m ) to infant at birth
17. GET ENOUGH SLEEP, AS SLEEP DEPRIVATION
TRIGGERS SEIZURES
18. MANAGE STRESS AND AVOID STRESSFUL SITUATIONS
70. 19. IF YOU HAVE SEIZURES REGULARLY, WEAR A
‘MEDICAL ALERT BRACELET’ THIS WILLHELP PEOPLE
TO KNOW ABOUT YOUR CONDITION
20. DRINK HALF GLASS OF GRAPE JUICE DAILY
21. LIMIT ALCOHOL INTAKE
22. AVOID SMOKING
23. LOW CALCIUM AND MAGNESIUM TRIGGERS
SEIZURES CONSUME FOODS RICH IN THEM
24. AVOID ALL ‘WHITE PRODUCTS’ LIKE:
a. White sugar
b. White flour
c. Table salt
d. White rice
71. 25. DO NOT SKIP MEALS, ESPECIALLY BREAKFAST
26. DO NOT CONSUME ARTIFICIAL SWEETENERS/
ADDITIVES
27. TAKE MEDICINES PRESCRIBED BY DOCTOR IN
CORRECT DOSAGES IN A TIMELY MANNER
28. DO NOT SKIP TAKING YOUR MEDICINES WITHOUT
DOCTOR’S APPROVAL
29. AVOID USAGE OF GINGKO BILOBA AND ST.JOHN’S
WORT FOR EPILEPSY ,UNLESS UNDER DOCTOR’S ADVICE
(SINCE THEY CAN INTERACT WITH AEDs)
30. FOLLOW A KETOGENIC DIET, COMPRISING:
a. High fat(nuts, cream, butter)
b. Low carbohydrate (starchy fruits, bread, pasta, grains,
sugar)
72. BIBLIOGRAPHY/ REFERENCE :
1. DAVENPORT.J.R; LEACH.P.J; ‘NEUROLOGICAL DISEASE:EPILEPSY’;DAVIDSON’S
PRINCIPLES AND PRACTICE OF MEDICINE; 22ND EDITION; Pg:1178-85
2. Tripathi.K.D; “Essentials of medical pharmacology”; 7th edition; Jaypee Publishers; “Anti-
epileptic drugs’; Pg:411-424
3. Dhillon.S; Sander.W.J; “Clinical pharmacy and therapeutics”; by Roger Walker; 5th edition;
“Epilepsy”; Pg: 489
4. Wells.G.Barbera;”Epilepsy”; Pharmacotherapy Handbook; by Joseph.T.Dipiro; Pg: 577
5. www.healthline.com
6. www.drugbank.com
7. www.webmd.com
8. http://www.thelancet.com/journals/abstract/’Top 10 home remedies To deal with Epilepsy’
9. Razzhaghi.A; “Seizure disorders”; “Comprehensive Pharmacy Review for NAPLEX by LEON
SHARGEL”; 8TH EDITION; Pg:743
10. Mc.Namara.C.J; “Pharmacotherapy of the Epilepsies”; Goodman & Gilman’s Pharmacological
basis of Therapeutics; 11th edition; Pg: 501